Multiple Myeloma Clinical Trial
Combined Haploidentical-Cord Blood Transplantation for Adults and Children
Summary
The primary objective is to assess the rate of engraftment with combined haploidentical-cord blood transplantation. The secondary objective is to evaluate the incidence and severity of acute and chronic graft-versus-host disease (GVHD).
Eligibility Criteria
Inclusion Criteria:
Patients will be eligible for this study if they have any one of the diseases that are known to be cured after allogeneic stem cell transplantation.
Relapsed or refractory acute leukemia (myeloid or lymphoid)
Acute leukemia in first remission at high-risk for recurrence
Chronic myelogenous leukemia in accelerated phase or blast-crisis
Chronic myelogenous leukemia in chronic phase
Recurrent or refractory malignant lymphoma or Hodgkin lymphoma
Chronic lymphocytic leukemia, relapsed or with poor prognostic features
Multiple myeloma
Myelodysplastic syndrome
Chronic myeloproliferative disease
Hemoglobinopathies
Aplastic anemia
Exclusion Criteria:
Zubrod performance status > 2
Life expectancy is severely limited by concomitant illness
Patients with severely decreased LVEF or impaired pulmonary function tests(PFT's)
Estimated Creatinine Clearance <50 ml/min
Serum bilirubin> 2.0 mg/dl or SGPT >3 x upper limit of normal
Evidence of chronic active hepatitis or cirrhosis
HIV-positive
Patient is pregnant
Patient or guardian not able to sign informed consent
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Chicago Illinois, 60637, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.